Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Moodys
McKinsey
Medtronic
Express Scripts
Mallinckrodt
Baxter

Last Updated: January 17, 2022

DrugPatentWatch Database Preview

Actavis Elizabeth Company Profile


Email this page to a colleague

« Back to Dashboard

What is the competitive landscape for ACTAVIS ELIZABETH, and what generic and branded alternatives to ACTAVIS ELIZABETH drugs are available?

ACTAVIS ELIZABETH has one hundred and sixteen approved drugs.

There are six tentative approvals on ACTAVIS ELIZABETH drugs.

Summary for Actavis Elizabeth
US Patents:0
Tradenames:76
Ingredients:76
NDAs:116
PTAB Cases with Actavis Elizabeth as petitioner: See PTAB cases with Actavis Elizabeth as petitioner

Drugs and US Patents for Actavis Elizabeth

Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Actavis Elizabeth BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE bisoprolol fumarate; hydrochlorothiazide TABLET;ORAL 075672-003 Sep 25, 2000 DISCN No No ⤷  Try it Free ⤷  Try it Free
Actavis Elizabeth ETODOLAC etodolac TABLET, EXTENDED RELEASE;ORAL 075696-001 Jul 31, 2000 DISCN No No ⤷  Try it Free ⤷  Try it Free
Actavis Elizabeth PREGABALIN pregabalin CAPSULE;ORAL 091025-002 Jul 9, 2020 AB RX No No ⤷  Try it Free ⤷  Try it Free
Actavis Elizabeth OXYCODONE HYDROCHLORIDE AND IBUPROFEN ibuprofen; oxycodone hydrochloride TABLET;ORAL 078769-001 Jan 4, 2008 DISCN No No ⤷  Try it Free ⤷  Try it Free
Actavis Elizabeth DOXAZOSIN MESYLATE doxazosin mesylate TABLET;ORAL 075574-004 Oct 18, 2000 DISCN No No ⤷  Try it Free ⤷  Try it Free
Actavis Elizabeth PREGABALIN pregabalin CAPSULE;ORAL 091025-006 Jul 9, 2020 AB RX No No ⤷  Try it Free ⤷  Try it Free
Actavis Elizabeth ROPINIROLE HYDROCHLORIDE ropinirole hydrochloride TABLET, EXTENDED RELEASE;ORAL 090869-001 May 17, 2012 AB RX No No ⤷  Try it Free ⤷  Try it Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Subscribe to access the full database, or Try it Free

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Moodys
Baxter
Colorcon
Johnson and Johnson
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

 
© Copyright 2002-2022 thinkBiotech LLC
ISSN: 2162-2639
Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2022 - 2023
 NCE-1 Patent Challenge Dates 2022 - 2023
 ClinicalTrialExchange - Connecting volunteers and trials
Preferred Citation:

Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2022, www.DrugPatentWatch.com.

Links

Follow DrugPatentWatch:

  DrugPatentWatch Linkedin Group